RTRX Retrophin Inc.

17.8
+0.8  (+5%)
Previous Close 17
Open 17.07
Price To Book 2.76
Market Cap 764,583,888
Shares 42,954,151
Volume 748,729
Short Ratio
Av. Daily Volume 440,738

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted August 6, 2019.
CNSA-001
Phenylketonuria (PKU)
Phase 3 top-line data due 3Q 2019.
RE-024 fosmetpantotenate
Pantothenate kinase-associated neurodegeneration (PKAN)
Phase 3 top-line data due 1H 2021.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
FDA Approval announced June 28, 2019.
New formulation of Thiola (tiopronin)
Cystinuria

Latest News

  1. Edited Transcript of RTRX earnings conference call or presentation 6-Aug-19 8:30pm GMT
  2. Retrophin (RTRX) Q2 2019 Earnings Call Transcript
  3. Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates
  4. Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
  5. Is Retrophin (NASDAQ:RTRX) A Risky Investment?
  6. Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
  7. Retrophin to Report Second Quarter 2019 Financial Results
  8. The Week Ahead In Biotech: Pending Clinical Readouts In Focus
  9. U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction
  10. An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued
  11. Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount?
  12. Shkreli and Retrophin resolve 'all outstanding disputes'
  13. Martin Shkreli settles all litigation with his former company Retrophin
  14. Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
  15. Is Retrophin, Inc.'s (NASDAQ:RTRX) Balance Sheet A Threat To Its Future?
  16. From prison, 'Pharma Bro' Martin Shkreli sues ex-colleagues for $30 million
  17. 'Pharma bro' Martin Shkreli sues Retrophin directors, ex-general counsel for more than $30 million from prison in Pennsylvania
  18. Retrophin to Present at Upcoming Investor Conferences